Back to top

Analyst Blog

Zacks Equity Research

Merck to Return Vernakalant Rights

MRK CRME

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Merck (MRK - Analyst Report) and Cardiome Pharma Corp. (CRME) recently announced that Cardiome will regain global marketing and development rights for the intravenous (IV) as well as the oral formulations of vernakalant from Merck.

The Merck/Cardiome agreement dates back to April 2009, when the companies announced a collaboration and licensing deal related to the development and commercialization of vernakalant. While Merck Sharp and Dohme Corp. gained exclusive global rights to oral vernakalant, Merck Sharp & Dohme (Switzerland) GmbH (another Merck affiliate) acquired exclusive rights to the intravenous (IV) formulation of vernakalant outside the US, Canada and Mexico. Merck acquired North American rights as well to the IV formulation in 2011.

However, earlier this year in March, Cardiome announced Merck’s decision to discontinue the development of the oral formulation of vernakalant. Merck decided to stop developing oral vernakalant based on its assessment of the regulatory environment and the time involved in the development process.

Merck and Cardiome were studying the candidate as a maintenance therapy for the long term prevention of atrial fibrillation recurrence.

Meanwhile, the IV formulation is approved in the EU under the trade name Brinavess for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. However, Brinavess’ development path in the US has not been smooth with the US Food and Drug Administration (FDA) placing a clinical hold on the development program for the IV formulation. A phase III study, ACT V, which was suspended in 2010, was terminated later.

Merck’s decision to return vernakalant rights reflects the company’s efforts to streamline its pipeline and allocate funds across its entire portfolio. As far as Cardiome is concerned, the company will most likely need to seek a partner for the commercialization and further development of vernakalant. Moreover, the company has a weak pipeline consisting of a few early stage projects.

We currently have a Neutral recommendation on both Merck and Cardiome. While Merck carries a Zacks #3 Rank (short-term Hold rating), Cardiome carries a Zacks #4 Rank (short-term Sell rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%